Cost-effectiveness of PARP inhibitors in malignancies: A systematic review.

Haiying DingChaoneng HeYinghui TongQilu FangXiufang MiLingya ChenWenxiu XinLuo Fang

Published in: PloS one (2022)

PARPi is potentially cost-effective for patients with ovarian, pancreatic, or prostate cancer. Genetic testing can improve the cost-effectiveness of PARPi.

Keyphrases

prostate cancer
radical prostatectomy
dna damage
dna repair
oxidative stress